Turn Therapeutics Inc. (TTRX) – What Are Researchers Saying About This Stock?

by · The Cerbat Gem

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) has been given an average rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $9.00.

Several brokerages have issued reports on TTRX. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Wall Street Zen lowered shares of Turn Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Finally, WBB Securities raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 target price on the stock in a research note on Friday, October 23rd.

Get Our Latest Stock Analysis on Turn Therapeutics

Institutional Investors Weigh In On Turn Therapeutics

Several large investors have recently modified their holdings of the stock. SteelPeak Wealth LLC grew its position in Turn Therapeutics by 0.7% in the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock valued at $3,616,000 after acquiring an additional 1,819 shares during the period. TD Waterhouse Canada Inc. acquired a new position in Turn Therapeutics during the third quarter worth $40,000. Jefferies Financial Group Inc. bought a new position in shares of Turn Therapeutics during the second quarter valued at $119,000. Bank of America Corp DE bought a new position in shares of Turn Therapeutics during the second quarter valued at $103,000. Finally, Ieq Capital LLC acquired a new stake in shares of Turn Therapeutics in the 2nd quarter valued at $1,660,000.

Turn Therapeutics Price Performance

Shares of Turn Therapeutics stock opened at $9.48 on Tuesday. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $16.45. The firm has a fifty day moving average price of $11.70 and a two-hundred day moving average price of $7.13. The company has a market cap of $289.42 million and a PE ratio of -32.69.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Analysts expect that Turn Therapeutics will post -0.40 EPS for the current year.

About Turn Therapeutics

(Get Free Report)

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.

Featured Articles